Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis.
October 14, 2019
· 3 min read